HYDROCHLOROTHIAZIDE; IRBESARTAN | N020758 | SANOFI AVENTIS US LLC
4 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (4)
Sort:
#001 — 12.5MG;75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▴
TABLET;ORAL | Approved: Sep 30, 1997
No patent or exclusivity listings for this strength.
#002 — 12.5MG;150MG
RLDAB
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Sep 30, 1997
#003 — 12.5MG;300MG
RLDAB
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Aug 31, 1998
#004 — 25MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**